What to expect in biopharma in 2023 in the Asia and beyond?

Hayakawa, head of targeted protein degradation at Astellas, gives us insights into the state of the biopharma industry in 2023.

Related Keywords

China ,Tsukuba ,Ibaraki ,Japan ,Yamanouchi ,Kanagawa ,Cambridge ,Cambridgeshire ,United Kingdom ,Japanese ,Masahiko Hayakawa ,Yamanouchi Pharmaceutical Co Ltd ,Astellas Pharma Inc ,San Francisco Bay ,Kirsten Rat Sarcoma Virus Oncogene Homolog ,